Beauty BlendBlend
Cosmetic-focused peptide blend for skin and hair research.
- Status
- Research / not approved
- Developer
- Compounded research-peptide blend; vendor-specific (no originator)
- Receptors / target
- Not a single target — combines GHK-Cu (copper tripeptide; collagen/ECM remodeling) and KPV (alpha-MSH-derived anti-inflammatory tripeptide); no characterized combined pharmacology
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- skin regeneration / anti-aging researchcollagen & extracellular-matrix synthesiswound-healing researchcutaneous anti-inflammatory research
Overview
Beauty Blend is a compounded research-peptide mixture most commonly combining the copper tripeptide GHK-Cu with the tripeptide KPV, marketed toward skin and cosmetic research. Composition is vendor-specific and not standardized — some suppliers instead pair GHK-Cu with BPC-157 and TB-500 (which is the separate "GLOW" formulation), so check the specific product. All components are supplied as research-use-only material, not for human or animal use. There are no clinical trials of the blend itself.
Mechanism
Any proposed activity rests on the individual peptides, not the mixture. GHK-Cu is studied for copper-dependent modulation of collagen and extracellular-matrix synthesis, antioxidant activity, and skin-remodeling signaling. KPV is an alpha-MSH-derived anti-inflammatory tripeptide acting through NF-kB and related pathways. The combined preparation has no characterized pharmacology of its own — interactions between the peptides in a single solution are unstudied.
Clinical evidence
There are no clinical trials of Beauty Blend as a combination product, and no human efficacy or safety data for the mixture. Evidence is limited to research on the individual components: GHK-Cu has small human topical/cosmetic studies (and one independent RCT that found no objective benefit after laser resurfacing), while KPV evidence is preclinical (cell and mouse models). Any inference of benefit is extrapolated from single-compound research and is not evidence for the blend.
Safety profile
No safety data exist for this combination in humans; combined-injection safety is entirely unstudied. Component-level signals are limited — GHK-Cu carries theoretical concerns around copper load with repeated or high-dose exposure, and injection-site reactions are a general risk for any reconstituted peptide. The core GHK-Cu + KPV version is not specifically WADA-listed, but note that vendor variants adding TB-500 would be WADA-prohibited. Research-use-only material is not sterility- or purity-assured. Nothing here is therapeutic or dosing guidance.
- Weeks
No trials of the blend exist. GHK-Cu skin studies ran over weeks (topical); KPV evidence is preclinical. Any combined timeline is anecdotal.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions (pain, redness, swelling)
- Theoretical copper-related effects with high or repeated GHK-Cu dosing
- Unknown effects from combined administration
- Research-grade purity / contamination risk
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- Human contraindication data for the GHK-Cu + KPV blend do not exist; combined-injection safety is unstudied
- Caution with conditions of copper overload (e.g., Wilson's disease) given the copper-carrying GHK-Cu component
- Avoid with known hypersensitivity to copper or to either tripeptide
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only)
Compare
- vs GHK-Cu
The standalone copper tripeptide in the blend; better characterized, with small human topical/cosmetic studies.
- vs KPV
The standalone alpha-MSH-derived anti-inflammatory tripeptide in the blend; its evidence is preclinical.
- vs GLOW
A related skin/repair blend that pairs GHK-Cu with BPC-157 and TB-500 instead of KPV — note the TB-500 makes GLOW WADA-prohibited.
FAQ
Is there evidence the Beauty Blend works?
There are no clinical trials of Beauty Blend as a combination product, and no human efficacy or safety data for the mixture. Evidence is limited to research on the individual components — GHK-Cu has small human topical studies (one RCT found no objective benefit after laser resurfacing) and KPV evidence is preclinical.
What is in Beauty Blend?
It most commonly combines the copper tripeptide GHK-Cu with the anti-inflammatory tripeptide KPV. Composition is vendor-specific and not standardized — some suppliers instead pair GHK-Cu with BPC-157 and TB-500 (the separate GLOW formulation), so check the specific product.
Is the blend safe?
No safety data exist for this combination in humans; combined-injection safety is entirely unstudied. GHK-Cu carries theoretical concerns around copper load with repeated or high-dose use, and research-grade material is not sterility- or purity-assured.
Is Beauty Blend FDA-approved?
No. It is a compounded research-use-only peptide blend that has not been evaluated by the FDA, and neither GHK-Cu nor KPV is an approved drug. It is not sold for human or animal use.
How is Beauty Blend used in research — injected or topical?
Both routes appear: some protocols use subcutaneous injection, others topical application. Note the underlying GHK-Cu evidence base is largely from topical cosmetic studies, so injectable use of the combination is even less characterized. There is no validated time-course for the blend; any schedule is anecdotal.
Is Beauty Blend banned in sport?
The core GHK-Cu + KPV version is not specifically named on the WADA list, but vendor variants that swap in or add TB-500 (such as the GLOW formulation) are WADA-prohibited. Always confirm the exact composition before assuming a product is permitted.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.